| Nov 12 |
Disc Medicine GAAP EPS of -$0.89 beats by $0.10
|
| Nov 12 |
Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Nov 11 |
Disc Medicine secures $200m financing to support trials
|
| Nov 8 |
Disc Medicine secures $200M in debt financing from Hercules Capital
|
| Nov 8 |
Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.
|
| Nov 5 |
Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
|
| Nov 4 |
Disc teases potential NDA for rare skin disorder drug
|
| Nov 4 |
Disc Medicine stock rallies 29% on FDA update for bitopertin
|
| Nov 4 |
Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval
|
| Nov 1 |
Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
|
